Document is current
Any future updates will be listed below
-
Authors
Yao, Shuyang https://orcid.org/0000-0001-9669-4470
Harder, Arvid
Darki, Fahimeh
Chang, Yu-Wei
Li, Ang https://orcid.org/0000-0002-1186-3448
Nikouei, Kasra
Volpe, Giovanni https://orcid.org/0000-0001-5057-1846
Lundström, Johan N. https://orcid.org/0000-0002-3529-8981
Zeng, Jian
Wray, Naomi R. https://orcid.org/0000-0001-7421-3357
Lu, Yi https://orcid.org/0000-0001-9933-3654
Sullivan, Patrick F. https://orcid.org/0000-0002-6619-873X
Hjerling-Leffler, Jens https://orcid.org/0000-0002-4539-1776
- License Information
-
More Information
Article History
Received: 7 August 2024
Accepted: 17 December 2024
First Online: 4 January 2025
Competing interests
: PFS is a scientific consultant and shareholder for Neumora Therapeutics. The remaining authors declare no competing interests.
